Shushan Hovsepyan: Some oral abstract sessions in pediatric oncology to keep on your radar at ASCO 2024
Shushan Hovsepyan shared a post on LinkedIn:
“ASCO 2024 is just around the corner and here are some oral abstract sessions in pediatric oncology to keep on your radar:
RMS13: A phase II trial using risk adapted focal proton beam radiation and/or surgery with the addition of maintenance chemotherapy in intermediate risk rhabdomyosarcoma
Jessica Gartrell St. Jude Children’s Research Hospital
Outcome of children and young adults with localized extremity rhabdomyosarcoma treated on Children’s Oncology Group trials
Rajkumar Venkatramani M.D. Children’s Oncology Group
CINSARC score use in pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in the Children’s Oncology Group (COG) studies ARST0332 and ARST1321
Rachel M Hurley Children’s Hospital of Philadelphia
Brigatinib monotherapy in children with R/R ALK+ ALCL, IMT, or other solid tumors: Results from the BrigaPED (ITCC-098) phase 1 study
Charlotte Rigaud ITCC Consortium
Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions
Elizabeth Fox St. Jude Children’s Research Hospital
Phase IB study of tovorafenib for children with relapsed/recurrent low-grade gliomas and other MAPK pathway activated tumors
Karen D. Wright Dana-Farber Cancer Institute
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial
Olaf Witt Hopp Children’s Cancer Center Heidelberg (KiTZ)
Vincristine (VCR) pharmacokinetics (PK) in infants dosed using a body surface area (BSA) banded dosing table and in older children dosed based on BSA: A pediatric early phase clinical trial network study (PEPN22P1).
Emily Blauel-Bocko Children’s Hospital Colorado
Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo – STING trial.
Mark Ranalli Nationwide Children’s Hospital
A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group
Ami V. Desai The University of Chicago Medical Center Children’s Oncology Group
Add your list below! See you soon in Chicago!”
Additional details.
Source: Shushan Hovsepyan/LinkedIn
Shushan Hovsepyan is a pediatric oncologist and adjunct assistant professor at the Yerevan State Medical University. Currently, she is the Editor-in-Chief of OncoDaily Medical Journal.
She completed her clinical at the National Institute of Cancer in Milan, Italy and at the St. Anna Children’s Research Hospital in Austria Furthermore, she held a research fellowship position at the European Organisation for Research and Treatment of Cancer in Brussels, Belgium.
Dr. Hovsepyan also completed the Postgraduate Harvard Medical School’s Effective Writing for Healthcare program. She is a former co-chair of the SIOP Global Health Network Education and Training Working Group..